A structured view of current advances, persistent gaps, and future directions in AI-enabled pharmaceutical innovation is offered, showing growing convergence between AI and precision therapeutics, but real-world application demands robust validation, collaboration, explainable AI, and global standards.
A paradigm shift toward autonomous scientific agents capable of causal reasoning and end-to-end experimental guidance is highlighted, and persistent challenges are discussed, including data bias, limited interpretability, and in silico-to-wet lab translation.
The evolving role of AI in modern drug discovery is discussed while highlighting the importance of explainable algorithms, high-quality biomedical data, real-world evidence, and interdisciplinary collaboration.
Mohsen Zabihi· Advances in Pharmacology and...· 0 citations
The analysis suggests that AI will become an increasingly important component of pharmaceutical workflows; however, long-term impact will depend less on algorithmic advancement alone and more on effective integration with biological validation, experimental rigor, clinical evidence, and scalable translational infrastru...
Andrew Matelis· American Journal of Student...· 0 citations
The conventional drug discovery pipeline is resource-intensive, time-consuming, and characterized by high attrition rates, often requiring more than a decade and billions of dollars to bring a single therapeutic agent to market. Drug repurposing identifying new therapeutic indications for approved or investigational dr...
Z. Malik, Kamran Ahmad, Sheheryar Ahmed· Computational biology and ch...· 0 citations
It is concluded that future progress will depend less on increasingly sophisticated algorithms than on trustworthy AI systems that improve scientific decision-making within iterative lead optimization workflows and ultimately enhance translational success in drug discovery.
F. A. Mohamed, A. M. K. El-sagheir· Medicinal Chemistry Research· 0 citations
This invited narrative review and platform perspective summarizes the concept and current implementation of an integrated Drug Discovery DX Platform (DXPF) that connects disease information and patient omics data to target gene/protein discovery, lead compound generation, and simulation-based evaluation.
Yasushi Okuno· Journal of Asian Association...· 0 citations
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduOct 18, 2026
A new computational approach reveals how cells communicate to assemble into tissues. This could accelerate stem cell engineering, improve disease models, and inform therapies.